New chemo cocktail aims to outperform standard treatment for advanced colon cancer
NCT ID NCT07309289
First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 26 times
Summary
This study tests whether a new chemotherapy combination (NALIRIFOX) plus targeted therapy works better than the standard treatment (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer that cannot be removed by surgery. About 144 adults who have not had prior treatment for their advanced disease will be randomly assigned to one of the two groups. The main goal is to see if the new combination improves the chance of living without the cancer getting worse for at least 18 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Zhongshan Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.